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DETERMINATION OF CYCLOSPORINE CONCENTRATION IN BILE 
Cyclosporine (CsA),* a cyclic undecapeptide of fungal origin, 
is a potent immunosuppressive drug used to prevent the rejec-
tion of transplanted kidneys, livers, and hearts in man. Elimi-
nation of the drug is primarily biliary; only about 6% of the 
dose appears in the urine. 
The disposition and metabolism of CsA remains poorly 
understood. Absorption from the gastrointestinal tract is in-
complete and variable, and it is possible that the drug undergoes 
enterohepatic recirculation. Venkataramanan et a1. observed 
increases in CsA blood levels following T tube clamping in liver 
transplant patients (1), and Kahan and coworkers noted the 
appearance of the drug in the ileostomy drainage of a patient 
(2). 
esA blood levels of transplant patients are routinely moni-
tored in our laboratory by radioimmunoassay (RIA) or high-
performance liquid chromatography (HPLC) of whole blood. 
The RIA measures esA and many of its metabolites, whereas 
HPLC specifically measures the parent compound. A modifi-
cation of both methods for determination of CsA in bile samples 
has been developed in our laboratory, and it has proved to be 
reliable in terms of accuracy, precision, and sensitivity. The 
determination of CsA concentration in bile is of potential value 
in the research setting as a tool for CsA disposition studies. 
Bile samples were collected from a T tube in the common 
bile duct of five patients who had recently undergone orthotopic 
liver transplantation. Blank bile for preparation of assay stand-
ards and controls was from a patient not receiving CsA. Sam-
ples were obtained at various times after a dose of CsA and 
Were stored at -20°C. CsA was administered as an oral dose 
(800-1200 mg; n = 3) or as a combination of i.v. infusion and 
oral dose (100-140 mg i.v., 450-1200 mg p.o.; n = 2). 
For RIA, CsA standards and controls were prepared using a 
stock solution of 2.5 mg CsA in 25 ml of HPLC-grade methanol. 
The flask was wrapped in foil and stored upright at -20°C. 
• Abbreviations used: CMI, cyclosporine metabolite index; esA, cy-
closporine; HPLC, high-performance liquid chromatography; RIA, ra-
dioimmunoassay. 
Two sets of standards, 10, 20, 40, 69, and 100 ~g/ml and 15, 40, 
50, and 80 J.Lg/ml, were prepared by pipetting the appropriate 
volumes of stock solution into glass flasks, evaporating the 
methanol under a stream of dry nitrogen, and adding 1.0 ml of 
blank bile. The flasks were covered with foil and stirred at 
room temperature for 1.5 hr. Each set of standards was diluted 
ilO-fold to the final concentration with assay buffer A (0.05 M 
TRIZMA, pH 8.5), aliquoted into capped plastic tubes, and 
frozen until needed. Patient samples were diluted 50-fold with 
buffer A before analysis. One set of standards was used to 
obtain a standard curve and the other set to assess the accuracy 
of the measurement. The Sandoz RIA kit was used to measure 
CsA in samples according to the manufacturer's instructions. 
HPLC bile standards and controls were prepared as above, 
but directly from the stock solution to yield the desired concen-
trations; no further dilution with buffer was performed. Patient 
samples were analyzed without dilution. HPLC determination 
of CsA was performed on a C18 reverse-phase Bondapack 
column, using a modification of the method of Sawchuk and 
Cartier (3). The column temperature was maintained at 70°C. 
Flow rate of the mobile phase, acetonitrile/methanol/distilled 
water (49/22/29 by volume), was 1.0 ml/min. Column effluent 
was monitored at 214 nm. Peak heights were measured elec-
tronically, and the ratio of CsA to the internal standard CsD 
was used to calculate drug concentration. 
An index of CsA metabolite production was calculated using 
the concentrations obtained by RIA and HPLC by the following 
equation: 
. . (RIA - HPLC) 
CsA metabohte mdex (CM!) = (RIA) 
A typical linear/log RIA standard curve of CsA in bile is 
shown in Figure 1. The assay is linear between bile' CsA 
concentrations of 0.2 and 2.0 J.Lg/mi. Patient samples were 
assayed in duplicate, and the coefficient of variation for dupli-
cates within the run was less than 10%. Precision of the assay 
in routine use was determined by analyzing 12 bile samples 
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FIGURE 1. Linear/log RIA standard curve for determination of cy-
closporine concentration in bile. 
from five patients in duplicate daily for 10 days. The standard 
deviation of the difference of duplicate values was obtained for 
each set of determination, and from this data a coefficient of 
variation was calculated using standard statistical methods. 
Thus, the average between run variation was 11 % with a range 
of 7%-14 %. The highest variation was observed in a bile sample 
that contained pulpy debris. Four bile controls loaded with 
different concentrations of CsA were assayed in duplicate with 
each run of patient samples, and recovery of added CsA was 
104±5.5% (Table 1). 
When CsA concentration was determined in bile using 
HPLC, the limit of sensitivity was 0.1 ~/mlI and recovery of 
CsA in bile controls at all levels of CsA averaged 95%. The 
coefficient of variation for bile standards .assayed on consecu-
tive days was approximately 10%. The volumes of patient bile 
samples received in the laboratory for assay were insufficient 
for repeat analyses by HPLC. 
Ten bile samples from four patients were assayed by RIA 
and HPLC for CsA concentration, and the results are shown 
in Table 2. Considerably higher values were obtained using 
RIA because of the high level of CsA metabolites present in 
bile. The actual metabolite concentration may be much higher 
than these values indicate, since CsA metabolites only partially 
crossreact with the antibody used in this assay. In contrast, 
HPLC, which specifically measures the parent drug- only, 
yielded values 8-48-fold lower than those obtained by ~K 
Table 2 also includes a CMI that appeared to be relatlvely 
constant in any given patient and fluctuated within a narrow 
range for all patients studied. The CMI was 0.98 for all three 
samples from patient C, even though the samples were collected 
at different times during the dosing interval. Similarly, patient 
B had an average CMI value of 0.93. 
The introduction of CsA for immunosuppression has been 
recognized as one of the major breakthroughs in organ trans-
plantation in recent years. A greater understanding of CsA 
disposition and metabolism in the human body may further 
enhance its usefulness. The question of relative amount of 
parent drug and metabolites at various dosages is an important 
one, especially if there is a saturation level above which the 
liver is unable to metabolize more drug in a single pass. 
A previous publication from this laboratory presented data 
on CsA levels in human bile (1). The analytical methods have 
since been modified to further increase precision, sensitivity, 
and CsA recovery. The most significant improvement has been 
the use of dry CsA for preparation of the stock standard solution 
instead of the standarri included in the Sandoz RIA kit, which 
had limited ,>ulubility in the blank bile such [[JOlt CsA recovery 
from standards and controls was variable and ·unacE:eptahhKID-Io~~f~: 
low. This, in turn, led to a variable underestimation of "f!j~~::~ •.. ;;>i.( 
concentration in bile. The present bile CsA method has a 
degree of precision, and recoveries are essentially 100%. 
The present study shows that the levels of parent CsA in 
are quite low, and it is unlikely that bile CsA undergoeS.,:< 
significant enterohepatic recirculation. This is in general!lgree,;'. 
ment with the results of Venkataramanan et a1. (1), who found::" 
that less than 1 % of the administered dose of CsA was excre+ft4.: 
in bile. The question remains, however, whether CsA metab:' , ["', 
lites, which are present in bile in very high concentrations,are;. 
recycled to any significant extent. This is important because if:' 
any of these metabolites possess immunosuppressive proper •.. 
ties, recycling may prolong the pharmacologic action of the: . 
drug. If, on the other hand, products of CsA metabolism are: " 
found to be toxic, their prolonged presence in the body could:' r 
be harmful. 
In this connection, the CMI could be a useful estimate of the 
level of CsA metabolites present in a sample. In blood, RIA 
determinations of CsA are two to three times higher than by 
HPLC (1), and the calculated CM! is found to be between 0.5 I 
and 0.7. In contrast, the CMI for bile samples is considerably: .. 
higher, around 0.93, consistent with the results of Venkatara," 
manan and coworkers (1), from whose data a CMI value of 
approximately 0.97 may be calculated. This may be expected;: 
as the metabolism of CsA is primarily hepatic. Unexpectedwaa. 
the rmding that the CM! values were virtually identical in a 
given patient, regardless of the time elapsed since the last dose 
of CsA (Table 2). These data imply that the hepatic breakdown 
of the drug is fairly constant throughout the dosing interval for 
the patients in this study. 
TABLE 1. Recovery of CsA added to control bile 
CsAadded 
(,.gJml) 
0.3 
0.8 
1.0 
1.6 
CsA measured (pg/ml) 
RIA HPLC' 
O.29±0.048 
0.85±O.079 
l.1±O.15 
1.7±0.13 
O.29±O.019 
O.81±O.075 
O.96±O.082 
1.7±O.13 
• n = 10 and 4, respectively, for RIA and HPLC for each. concentra· 
tion of CsA added to blank or- control bile. 
TABLE 2. RIA and HPLC determinations of cyclosporine 
concentration in bile samples at various times after a dose 
Patient 
A 
B 
C 
D 
Time after 
dose (hrl 
4 
1 
4 
9 
11 
12 
5 
7 
12 
2. 
RIA' 
97.7±12.8 
36.8±5.50 
47.9±7.95 
46.7±6.25 
39.9±5.10 
44.8±6.70 
29.6±3.85 
28.5±3.50 
21.5±3.15 
15.6+3.15 
CMI' 
HPLC 
6.69 0.93 
2.64 0.93 
4.63 0.90 
3.08 0.93 
2.55 0.94 
3.12 0.93 
0.714 0.98 
0.708 0.98 
0.451 0.98 
1.85 0.88 
• Mean (n = 10) and standard deviation are shown for RIA resul~K 
Insufficient sample volume prevented more than one HPLC detemll-
nation for each sample. 
b CMI.CsA metabolite index. 
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This method can be of value in the research setting for 
stub,s involving the dispositiun and metabolism of rsA. The 
results of RIA and HPLC CsA determinations in bile can be 
compared to estimate the fraction of total dose being excreted 
through the bile, as well as the amount of parent drug that is 
leaving the body un metabolized. 
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ENCAPSULATION OF CYCLOSPORINE BY PHOSPHATIDYLINOSITOL-CHOLESTEROL LIPOSOMES1 
Phospholipid vesicles (liposomes) are widely recognized as 
potential carriers of drugs (1) and other biologically active 
materials (2). Studies from our laboratory have demonstrated 
that they are appropriate for the reconstitution of cytochrome 
c oxidase (3, 4) and high density lipoproteins (5, 6), and may 
potentiate the immunogenicity of weak antigens (7). We have 
also shown that phosphatidylinositol-cholesterolliposomes are 
cytotoxic to tumor cell cultures (8). 
Cyclosporine, a cyclic peptide that comprises 11 amino acids 
(9), has recently been recognized to be a very potent immuno-
suppressant; however, it is associated with undesirable side 
effects-e.g., nephrotoxicity (10). Because cyclosporine is hy-
drophobic it may become entrapped within the phospholipid 
bilayer of liposomes when it interacts with them; the resulting 
complex may be advantageous for the delivery and targeting of 
cyclosporine. A preliminary report on liposome-encapsulated 
cyclosporine used in a rat model has recently appeared, but the 
composition of phospholipids and the preparation of liposomes 
were not disclosed (11). 
In this communication we report the preparation of phos-
phatidylinositol-cholesterolliposomes containing cyclosporine, 
and describe the centrifugation and the Sepharose-4B gel fil-
tration of the liposome-cyclosporine complex. Our results 
clearly show that phosphatidylinositol, cholesterol, and cyclo-
sporine form liposomes in a molar ratio of 2:1:0.22, establishing 
cyclosporine encapsulation by liposomes. 
Liposomes were prepared as described elsewhere (7), with 
the following modifications: 2.4 ~mol of soya bean phosphati-
dylinositol (Serdary Research Lab. Inc., London, Ontario), 
4X105 cpm of I-palmitoyl-2-[1-14C]-linoleoyl-sn-3-phosphati-
dylinositol (specific activity 58 mCi/mmol (Amersham, To-
ronto, Ontario), 1.2 ~mol of cholesterol (Sigma, St. Louis, MO), 
and 0.8 ~mol of cyclosporine (a gift from Sandoz A.G., Basel, 
Switzerland) were dissolved in 1 ml of chloroform and evapo-
rated to dryness. The residue was hydrated at 37°C for 2 hr 
with 1.5 ml of 0.15 M NaCl and then sonicated for 2 min. In 
1 This work was supported by a grant from the Medical Research 
Council of Canada. 
the control experiment cyclosporine was omitted and liposomes 
yielded a clear solution that was applied to a Sepharose-4B 
(Pharmacia, Uppsala, Sweden) column. 
Liposomes containing cyclosporine were milky and were 
subjected to centrifugation at 12,000 Xg for 10 min. The pellet 
containing 10.8.and 82.5% of starting [l4C]-phosphatidylinosi-
tol and cyclosporine, respectively, was not further investigated. 
The clear supernatant containing 1517 nmol of [l4C]-phospha-
tidylinositol and 170 nmol of cyclosporine was applied to the 
Sepharose-4B column and eluted with 0.15 M NaCL Fractions 
FIGURE 1. Sepharose-4B gel filtration. Elution pattern of A) phos-
phatidylinositoi:cholesterol liposomes and B) phosphatidylinosi-
tol:cholesterol:cyclosporine liposomes, prepared as described in meth-
ods. 
